February 26, 2014
This article was reported by Fox Business.
Fox Business reported that the U.S. Food and Drug Administration (FDA) awarded "breakthrough therapy designation" to Bristol-Myers Squibb's investigational treatment for hepatitis C virus (HCV) infection on February 24. This rare designation expedites the development and review process of drugs for serious or life-threatening conditions as FDA puts them on a fast-track approval process and gives the drug manufacturers intensive guidance. The approval for Bristol-Myers' combination therapy of chronic HCV infection comes after preliminary data from an ongoing late-stage trial in which the drug manufacturer is evaluating an all-oral regimen of daclatasvir and asunaprevir without ribavirin.
No comments have been made.
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.
|HIV Vaccine Induces Sustained HIV Remission in Proof-of-Concept Study|
|Incidence of All Cancers but Lung Cancer Drops After HIV Group Stops Smoking|
|What's Your Message to the Trump Administration About the Fight Against HIV?|
|PrEP Failure Case Underscores Importance of Regular HIV Testing|
|New HIV Capsid Inhibitor Strongly Stops HIV Replication at Two Steps|
|Classic Risk Factors Drive Heart Attack Rates More Than HIV Variables|